Adoptive T cell therapy (ACT) is a promising cancer treatment approach in which a patient’s T cells are removed, expanded or modified to target them against the cancer, and then re-infused back into the patient.
A major goal of Dr. Huse’s research is to identify genetic modifications that can enhance the functionality of therapeutic T cells in the context of ACT. He is particularly interested in the capacity of small RNAs, called microRNAs, to improve critical functional parameters like survival, proliferation, and cytotoxic activity. This novel strategy for enhancing therapeutic T cells has the potential to become a powerful and broadly applicable tool in next generation cell therapies, and he anticipates that his results will provide the foundation upon which improved therapies can be developed for humans with cancer.
Projects and Grants
Potentiation of Adoptive T Cell Therapy Via the MiR200c-EpCAM Axis
Memorial Sloan Kettering Cancer Center | Leukemia, Melanoma, Ovarian Cancer | 2020
Let's spread the word about Immunotherapy! Click to share this page with your community.